PROTAC-O4I2

Target: PROTAC-O4I2 selectively targets splicing factor 3B subunit 1, SF3B1.

Binding site: Its O4I2-derived ligand engages an SF3B1-associated splicing-modulator binding region.

Mechanism of action: PROTAC-O4I2 is a cereblon-recruiting SF3B1 degrader designed to convert SF3B1 ligand engagement into targeted protein degradation. The compound introduces a thalidomide-derived CRBN ligand into an SF3B1-directed scaffold, enabling recruitment of SF3B1 to CRL4CRBN ubiquitination machinery. Reported cellular studies show degradation of FLAG-SF3B1 in K562 cells and antiproliferative effects in SF3B1 wild-type, overexpressing, and K700E-mutant contexts. PROTAC-O4I2 is useful for studying spliceosome dependency, SF3B1 mutant biology, degradation-driven splicing perturbation, and apoptosis following targeted depletion of a core splicing factor.

• PROTAC-Mediated Oncoprotein Degradation: PROTAC-O4I2 serves as a powerful tool in cancer research by facilitating the selective degradation of oncogenic proteins. This targeted approach allows researchers to study the effects of protein knockdown on tumorigenic pathways, providing insights into cancer biology and potential therapeutic targets.

• Targeted Degradation in Neurodegeneration: By utilizing PROTAC-O4I2, scientists can explore the degradation of proteins implicated in neurodegenerative diseases. This application aids in dissecting the role of specific proteins in neuronal function and disease progression, offering a novel strategy for understanding neurodegenerative mechanisms.

• PROTAC-Driven Signal Pathway Analysis: Employing PROTAC-O4I2 enables the precise degradation of signaling proteins, allowing researchers to investigate complex cellular signaling networks. This application is crucial for elucidating the dynamics of signal transduction and identifying key nodes within pathways that can be targeted for therapeutic intervention.

• Selective Protein Degradation in Drug Discovery: PROTAC-O4I2 is instrumental in the field of drug discovery, where it is used to selectively degrade target proteins and validate drug targets. This approach accelerates the identification of viable therapeutic targets by demonstrating the functional consequences of protein depletion in cellular models.